Zepp Health Corporation (ZEPP)
NYSE: ZEPP · Real-Time Price · USD
12.06
-2.89 (-19.32%)
May 8, 2026, 12:52 PM EDT - Market open
← View all transcripts

Earnings Call: Q4 2022

Mar 21, 2023

Operator

Hello, ladies and gentlemen. Thank you for standing by for Zepp Health Corporation's Q4 and Full Year 2022 Earnings Conference Call. At this time, all participants are in listen-only mode. Today's conference call is being recorded. I will now turn the call over to your host, Miss Grace Zhang, Director of Investor Relations for the company. Please go ahead, Grace.

Grace Zhang
Director of Investor Relations, Zepp Health

Hello, everyone, and welcome to Zepp Health Corporation's Q4 and Full Year 2022 Earnings Conference Call. The company's financial and operating results were issued in a press release by the Newswire services earlier today and are posted online. You can also view the earnings press release and the slides referred on this call by visiting the IR section of the company's website at ir.com.com. Participating in today's call are Mr. Wang Huang, our Chairman of the Board of Directors and Chief Executive Officer, and Mr. Leon Cheng Deng, our Chief Financial Officer. The company's management will begin with prepared remarks, and the call will conclude with a Q&A session. Mr. Mike Yang, our Chief Operating Officer, will join us for the Q&A session.

Before we continue, please note that today's discussion will contain forward-looking statements made under the Safe Harbor Provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements involve inherent risks and uncertainties. As such, the company's actual results may be materially different from the views expressed today. Further information regarding this and other risks and uncertainties is included in the company's annual report on Form 20-F for the fiscal year ended December 31st, 2021, and other filings as filed with the U.S. Securities and Exchange Commission. The company does not assume any obligation to update any forward-looking statements except required under applicable law. Please also note that Zepp's earnings press release and this conference call include discussions of unaudited Zepp financial information as well as unaudited non-Zepp financial information.

Zepp's press release contains a reconciliation of the unaudited non-Zepp measures to the unaudited most directly comparable Zepp measures. I'll now turn the call over to our CEO, Mr. Wang Huang. Please go ahead.

Wang Huang
Chairman of the Board of Directors and CEO, Zepp Health

Hello, everyone. Thank you for joining our call. In 2022, we faced substantial macro challenges such as the ongoing COVID-19 pandemic, the Ukraine-Russia war, global inflation, and weakening consumer confidence. These factors affected our operations. While in Q4, consumer discretionary spending decreased due to macro economy uncertainties, particularly in Europe and the U.S. Against this backdrop, our Q4 revenue came in at RMB 1.1 billion, down 35.5% year-over-year, primarily due to decreased sales of Mi Band products. Our company foresaw the decline of their basic band market quarters ago and shifted our focus to self-branded watches. I am pleased to share with you that our self-branded products accounted for 77.4% of our sales during the Q4, compared to 57.7% in the same period last year.

We now offer various product lines for our self-branded products, including outdoor, sports and fitness, business, and basic watch lines. I still remember leading the company through its IPO five years ago. Our self-branded products only accounted as roughly 20% for the company's revenue. Over the past five years, we have successfully transformed our business from one which revenue was largely contributed by a single customer, to becoming a top global player in the smart wearables and healthcare services industries. Despite macro challenges, our self-branded products showed strong performance during Q4, with a 28.5% quarter-over-quarter revenue increase and continued gross margin expansion. The success is due to improved sales of our high-margin products and enhanced brand value together with our optimized solidly performancing sales channels, demonstrating our improved market position.

We believe that the smart wearable market has significant growth potential. We are confident in the growth trajectory of our Amazfit and Zepp products. We are committed to further expanding our self-branded product line. As we move forward, we will continue to focus on product innovation and optimizing our cost structure to drive profitability and reinforce our business resilience. We believe the smart wearable market has not achieved its full potential yet. For example, as we integrate GPT technology into our Zepp OS, we are able to offer a highly advanced and personalized experience for our users. This allows us to stand out in an increasingly competitive smart wearables industry by providing personalized sleep insights, coaching, goal tracking, nutrition advice, and health monitoring features, all with seamlessly integrated within our wearable devices.

Our dedication to improving the user experience and enhancing overall well-being sets us apart from our competitors and positions us as a leader in the industry. By continuing to leverage the power of GPT technology and other cutting-edge offerings, we are strategically expanding our reach and building long-term value. Our company has a long history of investing in cutting-edge technology to enhance our products and services. Several years ago, we invested in RISC-V architecture chip technology, and now we are able to use our own in-house designed low-power, high-performance RISC-V chip for smartwatches. This investment has allowed us to improve our smartwatches' performance and battery life. We are proud to leverage this technology in conjunction with our AI technology, similar to GPT, to offer tailor-made user experience. With the power of our RISC-V chips and AI technology, we can significantly enhance users' health and fitness performance.

We also utilize this technology to optimize user service, feedback analysis, marketing data analysis, AI coding, and testing, allowing us to increase operational efficiency and improve service quality. In addition to enabling users to design their own AI-empowered watch faces, we have also developed mini apps that are automatically designed by AI, similar to GPT technology. This allows us to offer users a highly personalized experience and sets us apart from our competitors in the smart wearable industry. Soon, we will integrate these technology advancements into our Zepp Coach function to elevate the user experience to new heights. Now, let's move to our global operations and products. Our new self-branded product has an impressive market performance, resulting in increased brand recognition among consumers worldwide in Q4.

Amazfit won NPD's Consumer Electronics Industry Performance Award in the fitness tracker category for top e-commerce U.S. market share gain, validating our product's competitiveness in the premium market. We also expanded our presence on the global stage by opening our Russia office in February. We successfully launched the Amazfit Falcon globally, which received recognition from the global high-end sports professional community, and our newly launched Amazfit GTS 4 and GTR 4 have been well received by consumers worldwide. In Q4, we remain concentrated on optimizing our cost structure as we strive for profitability and further enhance business resilience in 2023. We will continue with these cost-cutting initiatives while balancing cost controls with expenditures to fuel growth. We anticipate that these actions will meaningfully benefit our business operations in the long run.

We are extremely confident in our ability to seize market opportunities, enhance our product value, and continue to deliver additional shareholder value while providing users with more refined and comprehensive healthcare products and services. We believe that by optimizing our cost structure and balancing cost controls with investment in growth, we can continue to enhance our product value and improve margin. Rather than focus solely on quantity, we prioritize quality growth, and aim to win the competition in advanced markets like Europe and North America. Even in the face of global microeconomy uncertainty, we remain committed to providing cutting-edge technology and products, thus stay at the forefront of wellness solutions. Thank you again for joining us today. I will now turn the call over to Leon to go over the highlights of our Q4 financial results.

Leon Cheng Deng
CFO, Zepp Health

Thank you, Wang. Greetings, everyone. I would like to begin by discussing the key metrics of our Q4 financial results. Our Q4 revenue coming at the lower end of our guidance range, approximately RMB 1.1 billion, reflecting a 35.5% year-over-year decrease. We all know, this quarter was marked by macro headwinds as ongoing geopolitical tensions and lower discretionary spending persisted, particularly in Europe and the U.S. A result, consumers remained cautious with their household budgets, fearing a recession and inflationary pressures. Our sales in China were also impacted by lower consumer spending, specifically during the months of November and December. The COVID-19 pandemic outbreak and policies dampened consumer confidence amid macro uncertainty. Our supply chain was affected by the sudden lifting of COVID-19 restrictions in China, causing delays in some of our new self-branded product launches.

Consequently, this has net adverse impact on our Q1 sales as well. At the same time, we're encouraged by the bright spots we have seen in many parts of our business. As Wang mentioned, our self-branded products comprised 77.4% of total sales, compared to 57.7% for the same period last year. Moving forward, we're confident that our self-branded products will gain more traction as we continue to improve our product capabilities and increase brand awareness on a global scale. Let's now take a closer look at our gross margin, another bright spot in the quarter's performance. Our gross margin can be influenced by various factors such as product mix, product launch timing, and product life cycles, including model upgrades.

Despite the challenges we faced during the quarter, we achieved a year-high gross margin of 20.7%, compared to 19.3% in Q4 2021, and 19.1% in Q3 2022. This improvement was mainly driven by the successful launch of our margin-accretive new products and the optimization of our product and channel mix. As we continue to implement these proven initiatives, we're confident that we can sustain our positive gross margin trend into 2023. Turning now to costs. As we have discussed, costs have been a key focal point for our company, both in terms of their absolute amount and then as a percentage of sales. Since Q3 2020, we have been pleased to see a trend towards a decrease in total operating expenses while still making strategic investments to fuel growth.

Our company's adjusted operating expenses, excluding share-based compensation for the Q4 of 2022, were RMB 277.6 million, reflecting a year-over-year decrease of 5.9% and a quarter-over-quarter decrease of 6.1%. However, if we exclude severance payments of RMB 10 million, our Q4 operating expenses would be RMB 267 million. While we acknowledge that reducing fixed costs can be challenging, we're taking further steps to control our expenses and have already made good progress in cutting our expenses run rates. Looking ahead, we expect our total operating expenses to reach approximately RMB 250 million or lower in the coming quarters, which represents a significant decrease of around 20% or more from the average of RMB 300 million per quarter in 2022.

We'll continue to rightsize our optimization and streamline our cost base in order to achieve profitability in the coming quarters. Spending on R&D in Q4, 2022 was RMB 114.3 million, net increase of 21.9% year-over-year, which was partly due to the lower government subsidy received. If we exclude that factor, our R&D expenses remain slightly down versus the Q4 of 2021, thanks to our efficient product develop processes. Selling and the marketing expenses were RMB 125.1 million, 17.8% lower year-over-year, mainly due to pruning of our retail channels in Q4. At the same time, we continue to make investments selectively in various international markets and sales channel expansion through digital marketing initiatives, and also partnerships with leading global sales platforms. These investments are critical to drive our long-term organic growth.

Our Q4 expenses were RMB 53.4 million, which is almost in line with the Q3 of 2022, and a 17.5% decline compared with RMB 64.7 million in the Q4 of 2021. We believe that this decrease reflects our execution excellence and reconfirms the effectiveness of our of our expense control strategies. Our non-GAAP operating results improved throughout the year. In Q4 being the best performing quarter in 2022 from a percentage perspective. This result demonstrated a sequential improvement in our cost control given Q4's smaller revenue scale. Our adjusted net loss in the quarter was RMB 60.3 million, compared with RMB 52 million in the Q4 of 2021. In the Q4, the company wrote down RMB 30.1 million valuation allowance of deferred tax assets.

Excluding share-based compensation, the one-off severance packages and the deferred tax asset impact, the adjusted net loss was RMB 20.1 million in the Q4. Turning to the balance sheet. Our cash flow has remained strong thanks to our enhanced efficiency in working capital management. In Q4, we generated positive cash flow from operations, some of which were used to retire certain short-term debts. During the Q4, we continued to manage our inventory with precision, successfully reducing our inventory balance to RMB 1 billion, compared to RMB 1.25 billion at the end of 2021, and down from its peak of RMB 1.5 billion in 2022. In November 2021, the board approved the allocation of up to $20 million toward a share repurchase program.

In Q4 2022, we continued our repurchase program, a testament to our ongoing confidence on our long-term growth prospect. We have bought back $10.3 million worth of shares by the end of December, and we intended to carry on with this buyback program. Moving on to our outlook. In light of ongoing macroeconomic challenges, our guidance for the Q1 of 2023 currently projects net revenue to be between RMB 0.6 billion and RMB 0.75 billion, compared with RMB 0.76 billion for this Q1 of 2022. Please note that this outlook reflects continued uncertainty around the potential effects of the COVID-19 pandemic on sales and lower discretionary consumer spending, especially in our international markets and global macro weakness.

We have seen some positive signs, and the year may be somewhat back and loaded as we gradually release our new products. This concludes our prepared remarks. We'll now open the call for questions. Operator, please go ahead.

Operator

Thank you. We'll now begin the question-and-answer session. To ask a question, you may press star then one on your telephone keypad. If you are using a speakerphone, please pick up your handset before pressing the keys. If at any time your question has been addressed and you would like to withdraw your question, please press star then two. For the benefit of all participants on today's call, if you wish to ask your question to the company's management in Chinese, please immediately repeat your question in English. At this time, we will pause momentarily to assemble our roster. The first question comes from Lisa Lee with Alpha Research. Please go ahead.

Lisa Lee
Equity Research Analyst, Alpha Research

Thank you. Thank you management for taking my questions. I have two questions. The first one is, your Q4 margin looks quite strong. What has driven this performance? Was the improvement due to self-branded products? Secondly, how should we think about the full year 2023 in terms of revenue growth, gross margin, SG&A, et cetera? Thank you.

Leon Cheng Deng
CFO, Zepp Health

Thank you, Lisa. I mean, let me quickly come back on your first question. Yes, the gross margin improvement in Q4 is majority driven by the gross margin performance of the self-branded products. So there are two things to it. Number one, we improved on the product mix. As we mentioned that, in the past, the Xiaomi product has always been standing for a majority part of our revenue base. In Q4 2022, it's actually reversed. Actually, our self-branded products stands for more than 77% of the overall mix. For the quarter. I think product mix definitely plays a role, and you all know that our self-branded products carries a higher margin than the Xiaomi branded products.

Number two is also on the channel mix. What we did in Q4 and also in the second half of 2022 is to gradually pruning on our channel, our retail partners, right? We try to look at the probabilities selectively on the retail partners and try to prune those ones which are not making money. In essence, the product and channel mix has been one of the reasons driven the overall gross margin up for the company for the Q4. We see this actually, this trend to continue in 2023. Then on 2023 full year, normally we don't guide for the full year performance. We only guide for the upfront 1 quarter performance.

I think I could give you a few, some colors on how we look at the full year. I think at this moment, we're cautiously optimistic about the full year. Because according to IDC data and some other third party market research institutions report, the overall wealth of market for 2023 is still pointing to a small growth. I think it's a single digit growth for the full year for 2023. What I can say is that our market share among the global players has remained relatively stable and also improving in the course of 2022. We're cautiously optimistic about the full year of 2023.

However, I think the year is probably going to be a little bit back-end loaded. Because also from a seasonality perspective, the high season, sales season for our industry always centered around Q3 and Q4. In this case, I think over a full year, we're still seeing probably our revenue is going to be cautiously optimistic, but more skewed towards second half of this year. On the gross margin, I have mentioned that our gross margin performance, we have seen that there's an increasing trend quarter by quarter in 2022, and we expect that I think 2022 Q4, we end the quarter with 20.7%. I think we see this trend gradually improving also into 2023.

We because we also think the product mix and the channel mix is going to continue to improve for our company. On the cost, operating cost, overall, I think I also just mentioned that we have managed to tune the cost down to a level in Q4, whereby if you exclude the severance cost, it stands at RMB 270 million per quarter, whereby the full year run rate was RMB 300 million per quarter for 2022. We expect that this number is going to be further tuned down to a level of RMB 250 million per quarter or even lower per quarter for 2023.

Overall, I think given all the things which I just mentioned, we think we are on a good track to return to profitability in 2023, hopefully in the second half of the year. If not earlier.

Lisa Lee
Equity Research Analyst, Alpha Research

That's very clear. Thank you. If I may, can I add one more question? Can you also discuss your performance in different regions? For example, now we're seeing, I guess, a recovery trend in China, not so much in Europe and North America. Can you know, talk about your performance in different regions, give us more colors there? Thank you.

Leon Cheng Deng
CFO, Zepp Health

Okay. Now, I think, yes, in China, you see gradually a recovering trend, although relatively slow in Q1 2023. I think this is going to improve as we go in the year. China actually stands to a small part of our overall self-branded product portfolio. Our biggest market is actually in the European markets, whereby we are kind of impacted a little bit by the discretionary income cut because of the inflation pressures in Europe, and also to some extent by the Ukraine and Russia war. We're actually mitigating that.

Then, in February this year, we even opened a regional office in Warsaw, on top of the other, satellite offices which we already had in Europe. We see, certain bright spots in Europe, especially in Eastern Europe areas. Actually, our market share has went up quite dramatically, during the year in Poland, especially. We see that in Southern Europe market, we're also actually maintaining our share and, improving our share. Europe has, and will remain as, a cornerstone for our, regional performance, for our company.

There's a bright spot in United States, as mentioned by Wei, in his script before, we won one of the third parties, Consumer Electronics Industry Performance Awards for the fitness tracker category for the top e-commerce U.S. market share gain in 2022. Actually, we gained the market share from nowhere to a double-digit number in the course of 2022. We think U.S. will continue to act as a growth engine for ourselves in 2023 and beyond. I think those are obviously the ASEAN markets is a good emerging market whereby we think we still have quite some opportunities, especially in Korean and Japanese markets to actually grow ourselves even further than what we currently have.

I think there are, yes, we're living in an inflationary and consumer discretionary cut type of environment. However, we still see bright spots in different parts of the world whereby we believe there are still a huge potential for us to tap in 2023 and beyond.

Lisa Lee
Equity Research Analyst, Alpha Research

Thank you.

Operator

The next question comes from Ian Luo with Tianfeng Securities. Please go ahead.

Ian Luo
Analyst, Tianfeng Securities

Hi, management. Thank you for taking my questions. Congratulations to the Q4, very good result. I have two questions. First is about your gross margin. We have noticed many IC price have fallen significantly since last year. How can we measure the impact on the company's gross margin? Thank you.

Leon Cheng Deng
CFO, Zepp Health

Yeah, Ian, thank you. I think in so far, at least in Q1, we haven't seen too much of the price decrease. In other words, the benefit of IC price going down, which should in turn translate into a better margin per se for ourselves. Number one, I think it takes a few quarters for the price to be reflected in our BOM material cost, because most of the purchase we make, it's a long lead time purchase, especially on ICs, which we lock in the price already a few quarters before the current quarter. I think in so far, we didn't see too much of that benefit in our gross margin.

As you mentioned, we noticed that there's a cost price going down for the IC in the industry. I think in the coming quarters, we probably would see that benefit flowing into our gross margin, and that will in turn also increase our gross margin performance even further than what we have mentioned just now.

Ian Luo
Analyst, Tianfeng Securities

Okay. Okay. Thank you. The second is about ChatGPT, very popular topic these days. We think this is a good, very good opportunity for Zepp Health. Could you give us a more detailed outlook on the, on your product future plan about the ChatGPT application? Thank you.

Leon Cheng Deng
CFO, Zepp Health

Yeah. No, ChatGPT is actually a very interesting thing, but it's not only a buzzword for us. It's really has been used in many parts of our operations, right? I think there are two folds to it. Number one is we have applied ChatGPT in our basic processes. Think about customer care. Think about listening to customers' insights. Think about linking the APIs towards our research and development processes and help us to find out errors and code better, for example, right?

For, I think we have integrated ChatGPT in our basic day-to-day working processes in our company, because we have always been a technology-driven companies, and we use most advanced technology whenever we saw there's a potential to it, right? Number two, I think, which is different than the other parties. For example, if you look at Apple, they also have a ChatGPT application, but the only thing what it does is basically running ChatGPT on the watch instead of on the phone, and then it's just a different platform.

What we have done is we have integrated ChatGPT into our Zepp OS, and in turn, that actually helps us to tailor and look at the user's data and help user to make a tailor nate program. For example, on the watch faces, getting to know their insights, sleep insights, on AI coaching, on goal tracking, et cetera, better than what we can do without the GPT, right? I think we're one of the first wearable companies to apply GPT to this extent in the industry, and we will continue to do so.

Ian Luo
Analyst, Tianfeng Securities

Okay. Thank you. Thank you very clear. Cheers.

Operator

As there are no further questions now, I'd like to turn the call back over to the company for closing remarks.

Grace Zhang
Director of Investor Relations, Zepp Health

Thank you once again for joining us today. If you have further questions, please feel free to contact Zepp's Investor Relations Department through the contact information provided on our website. This concludes this conference call. You may now disconnect your line. Thank you.

Operator

Again, the conference has ended. You may disconnect your line. Thank you.

Powered by